Cargando…

Grover’s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy

BACKGROUND: Dermatologic toxicity is an important adverse effect of immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death 1 receptor (PD-1) or PD ligand 1 (PD-L1). Skin toxicity most commonly includes a maculopapular erythematous rash a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koelzer, Viktor H., Buser, Tobias, Willi, Niels, Rothschild, Sacha I., Wicki, Andreas, Schiller, Peter, Cathomas, Gieri, Zippelius, Alfred, Mertz, Kirsten D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986338/ https://www.ncbi.nlm.nih.gov/pubmed/27532022 http://dx.doi.org/10.1186/s40425-016-0151-z

Ejemplares similares

Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study
por: Koelzer, Viktor H., et al.
Publicado: (2016)

Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors
por: Paasinen-Sohns, Aino, et al.
Publicado: (2017)

Colorectal Choriocarcinoma in a Patient with Probable Lynch Syndrome
por: Koelzer, Viktor H., et al.
Publicado: (2016)

Alpha 1-antitrypsin retention in an ectopic liver
por: Dettmer, Matthias, et al.
Publicado: (2011)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
por: Jeter, Joanne M., et al.
Publicado: (2012)

Ipilimumab cystic hypophysitis mimicking metastatic melanoma
por: Wallace, John, et al.
Publicado: (2018)

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Validation of Pretreatment Prognostic Factors and Prognostic Staging Systems for Small Cell Lung Cancer in a Real-World Data Set
por: Hagmann, Raphael, et al.
Publicado: (2022)

Interleukin-33 in human gliomas: Expression and prognostic significance
por: GRAMATZKI, DOROTHEE, et al.
Publicado: (2016)

Two distinct immunopathological profiles in autopsy lungs of COVID-19
por: Nienhold, Ronny, et al.
Publicado: (2020)

Profile of ipilimumab and its role in the treatment of metastatic melanoma
por: Patel, Sapna P, et al.
Publicado: (2011)

Ipilimumab in the treatment of metastatic melanoma: management of adverse events
por: Della Vittoria Scarpati, Giuseppina, et al.
Publicado: (2014)

Predictors of toxicity for metastatic melanoma patients treated with ipilimumab
por: Valpione, Sara, et al.
Publicado: (2015)

Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma
por: Formozo, A. A., et al.
Publicado: (2021)

Giant ectopic liver, hepatocellular carcinoma and pachydermia-a rare genetic syndrome?
por: Dettmer, Matthias, et al.
Publicado: (2011)

Grover F. Powers. In memoriam.
por: Gordon, H. H.
Publicado: (1969)

Bibliography of Grover f. Powers
Publicado: (1952)

Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
por: Chmielowski, Bartosz
Publicado: (2013)

Acute visual loss after ipilimumab treatment for metastatic melanoma
por: Wilson, Melissa A., et al.
Publicado: (2016)

Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma
por: Montes, Vera, et al.
Publicado: (2018)

Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma
por: Hanley, T, et al.
Publicado: (2018)

Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma
por: Chu, Michael P., et al.
Publicado: (2020)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience
por: Hagmann, Raphael, et al.
Publicado: (2015)

Ipilimumab: Melanoma and beyond
por: Patel, Vishal, et al.
Publicado: (2011)

PIK3CA in Colorectal Cancer
por: Cathomas, Gieri
Publicado: (2014)

Grover Francis Powers and Pediatrics at Yale
por: Darrow, Daniel C.
Publicado: (1952)

Case for diagnosis. Atypical Grover’s disease()()
por: Vargas-Mora, Pablo, et al.
Publicado: (2021)

Grover disease associated with docetaxel chemotherapy
por: Afvari, Shawn, et al.
Publicado: (2022)

An Unusual Trigger of Grover’s Disease (GD)
por: Haniff, Shaniza, et al.
Publicado: (2023)

Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
por: Piérard, Gérald E., et al.
Publicado: (2012)

Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma
por: Hahn, Laura, et al.
Publicado: (2016)

Treatment of Ipilimumab Induced Graves' Disease in a Patient with Metastatic Melanoma
por: Azmat, Umal, et al.
Publicado: (2016)

Metastatic melanoma patients’ sensitivity to ipilimumab cannot be predicted by tumor characteristics
por: Rossfeld, Kara, et al.
Publicado: (2017)

Ipilimumab and Nivolumab-Induced Colitis in a Patient With Recurrent Metastatic Melanoma
por: Moein, Hamid-Reza, et al.
Publicado: (2021)

Unbiased screen for pathogens in human paraffin-embedded tissue samples by whole genome sequencing and metagenomics
por: Nienhold, Ronny, et al.
Publicado: (2022)

Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort
por: Conen, Katrin, et al.
Publicado: (2016)

Use of ipilimumab in the treatment of melanoma
por: Acharya, Utkarsh H, et al.
Publicado: (2013)

Ipilimumab-Induced Neutropenia in Melanoma
por: Ban-Hoefen, Makiko, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1t5bmu0o2q1mjotgvh8snt6aee